$NOVO B (+2.51%) Compared to tirzepatide of $LLY (-1.17%) a 2.4-milligram dose of Wegovy showed a significantly higher risk reduction of 57 percent higher risk reduction for heart attack, stroke and cardiovascular-related death or death from any cause during treatment without gaps of more than 30 days, according to the Danish drug manufacturer.
Data from more than 21,000 patients presented at the European Society of Cardiology meeting in Madrid also showed that the risk of heart disease and death from any cause decreased by 29 percent in Wegovy users compared to tirzepatide users, regardless of any gaps in treatment.
The results could give Novo a boost, as the company has lost market share to Zepbound in the US.
Source: https://de.tradingview.com/news/reuters.com,2025:newsml_L8N3UN05O:0/